Md Ashraf-Uz-Zaman

Dr. Md Ashraf-Uz-Zaman

Baylor College of Medicine, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RMRAJ MONGRE
RAJ MONGRE
CMChandra Mishra
Chandra Mishra
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
APAmresh Prakash
Amresh Prakash
SJSamil Jung
Samil Jung
MLMyeong-Sok Lee
Myeong-Sok Lee
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.

24 September 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Md Ashraf-Uz-ZamanMd Ashraf-Uz-Zaman
Md Ashraf-Uz-Zaman
SSSadisna Shahi
Sadisna Shahi
RARacheal Akwii
Racheal Akwii
SSSanaullah Sajib
Sanaullah Sajib
MFMohammad Jodeiri Farshbaf
Mohammad Jodeiri Farshbaf
NGNadezhda German
Nadezhda German

9 January 2024 in ACS Infectious Diseases
Verified
Journal Article
Closed access
Md Ashraf-Uz-ZamanMd Ashraf-Uz-Zaman
Md Ashraf-Uz-Zaman
TCTeck Khiang Chua
Teck Khiang Chua
Xin LiXin Li
Xin Li
YYYuan Yao
Yuan Yao
BMBala Krishna Moku
Bala Krishna Moku
YSYongcheng Song
Yongcheng Song

3 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Xin LiXin Li
Xin Li
XWXiaowei Wu
Xiaowei Wu
SNShenyou Nie
Shenyou Nie
JZJidong Zhao
Jidong Zhao
YYYuan Yao
Yuan Yao
YSYongcheng Song
Yongcheng Song
Chromosomal translocations involving the mixed lineage leukemia (MLL) gene cause 5–10% acute leukemias with poor clinical outcomes. Protein–protein interactions (PPI) between the most frequent MLL fusion partner proteins AF9/ENL and AF4 or histone methyltransferase DOT1L are drug targets for MLL-rearranged (MLL-r) leukemia. Several benzothiophene-carboxamide compounds were identified as novel inhibitors of these PPIs with IC50 values as low as 1.6 μM. Structure–activity relationship studies of 77 benzothiophene and related indole and benzofuran compounds show that a 4-piperidin-1-ylphenyl or 4-pyrrolidin-1-ylphenyl substituent is essential for the activity. The inhibitors suppressed expression of MLL target genes HoxA9, Meis1 and Myc, and selectively inhibited proliferation of MLL-r and other acute myeloid leukemia cells with EC50 values as low as 4.7 μM. These inhibitors are useful chemical probes for biological studies of AF9/ENL, as well as pharmacological leads for further drug development against MLL-r and other leukemias.

20 April 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Md Ashraf-Uz-ZamanMd Ashraf-Uz-Zaman
Md Ashraf-Uz-Zaman
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
TAThomas Abbruscato
Thomas Abbruscato
NGNadezhda German
Nadezhda German
Neurodegenerative disorders are continually increasing in incidence due to higher life expectancy. Currently, limited therapeutic strategies are available for affected patients, most targeting symptomatic treatment. mTOR pathway is identified as important player in neurogenesis that modulates healthy neuron growth and differentiation. Moreover, many neurodegenerative disorders are associated with downregulated mTOR signaling. However, mTOR activation can also lead to uncontrolled cell proliferation, promoting cancer. This careful balance limits the development of mTOR as a target for modulation of neuronal growth. Recently, selected classes of antidepressants were reported to activate mTOR pathways, causing dendritic outgrowth and increased synaptic protein levels. Although results were promising, they require treatment with up to 100 μM of tested compounds. To identify potential utilization of penfluridol, an anti‐psychotic agent, as a neuron growth modulator, we have screened this compound and its analogs using reported methodology. Although no activity was observed for PFL, one of its analogs, PF331, promoted neurogenesis in primary neurons. In particular, treatment with PF331 (100 nM,1 μM) for 5 days during reoxygenation (post‐stroke conditions) resulted in improved neurite outgrowth. At the same time, no effect on the viability of the primary neurons was observed under normoxic conditions and during the reperfusion stage. Further, we have established that observed activity was not related to the overstimulation of mTOR pathway, but rather to the compound’s ability to restore mTOR activation to the pre‐stress levels. We hypothesized that PF331 will have minimal impact on cancer proliferation and confirmed it in vivo , where our compound had no effect on cancer growth. Stroke is one of the pathological conditions characterized by hypoxia‐induced damage to neurons. Hence, we have proposed to evaluate our compound for the ability to lessen hypoxia‐induced damage using in‐vivo stroke model with prior confirmation of the ability of PF331 to cross the BBB in vivo and to achieve desired levels in the brain. In conclusion, PF331 has shown the ability to promote neurite outgrowth in primary neurons and restore mTOR activation in the hypoxic in vitro model. Because of its biological activity and favorable in vivo PK profile, we envision that this compound is a potential candidate for the treatment of neurodegenerative diseases, such as stroke. Evaluation of the effect of PF331 on primary neurons Evaluation of the effect of PF331 on of primary neurons. Neurons were subjected to 3 hrs of OGD followed by 4 (A and B)/ 5 (C) days of oxygenation to mimic ischemia reperfusion injury. (A–B) OGD reperfusion (OGDR) down‐regulates mTOR and ERK compared to normoxic (Nor) condition whereas treatment with Compound PF331 activates mTOR and ERK. (C) PF331 facilitates dendritic outgrowth and increased number of synapses. Figure 1